Fairvalue-Calculator Fairvalue-Calculator
EN DE

Aarti Drugs Limited (AARTIDRUGS) Fair Value & Analysis

Healthcare · IN · Market cap ₹34.1B

Price₹372.70
Fair Value₹356.81
Upside-4.3%
Quality97/100
Evidence: High Range ₹165.91 – ₹501.76

Fair value as of: Jun 29, 2026

✦ Which stocks are undervalued right now? Check free Discover now →

Analysis

Aarti Drugs Limited (AARTIDRUGS) currently trades at ₹372.70, while our model-based Fair Value estimate is ₹356.81 — implying the stock looks roughly 4.3% overvalued today. We read business quality at 97/100 (high quality), in the Healthcare sector. Bear case: priced above our estimate, the market already discounts strong expectations. Bull case: above-average quality can justify a premium — the entry price still matters most (evidence: high).

About the company

Aarti Drugs Limited, through its subsidiaries, manufactures and markets active pharmaceutical ingredients (APIs), pharmaceutical intermediates, specialty chemicals, and formulations in India and internationally. The company offers aceclofenac, celecoxib, diclofenac sodium, diclodenac potassium, diclofenac diethylamine, diclofenac resinate, diclofenac epolamine, nimesulide, ciprofloxacin HCL, enrofloxacin base, gatifloxacin sesquihydrate, levofloxacin base, norfloxacin, ofloxacin, metronidazole, metronidazole benzoate, ornidazole, secnidazole, tinidazole, clopidogrel bisulphate, ticlopidine HCL, metformin HCL, pioglitazone HCL, teneligliptin, vildagliptin, fluconazole, ketoconazole, tolnaftate, zolpidem tartrate, niacin, raloxifene HCL, and acamprosate. It also provides benzene sulphonyl chloride, benzene sulphonic acid, methyl benzenesulfonate, sodium benzene sulfinate, para toluene sulphonyl chloride, methyl para toluenesulfonate, sodium para toluenesulfinate, para chlorobenzenesul…

Open the full interactive analysis →

Similar stocks

Jiangsu Hengrui Pharmaceuticals Co (600276) -37% Sun Pharmaceutical Industries Limited (SUNPHARMA) -44% Zoetis Inc (Z1TS34) -1% Hansoh Pharmaceutical Group (3692) -37% Divi's Laboratories Limited (DIVISLAB) -70% Swedish Orphan Biovitrum AB (SOBI) -54%

Frequently asked questions

Is Aarti Drugs Limited (AARTIDRUGS) undervalued?
As of Jun 29, 2026, our model estimates a fair value of ₹356.81 versus a price of ₹372.70 — about −4% (overvalued). Model-based estimate, not financial advice.
What is the fair value of AARTIDRUGS?
Our 21-model fair value for Aarti Drugs Limited is ₹356.81 (as of Jun 29, 2026), built from audited fundamentals. The current price is ₹372.70.
What is the quality score of AARTIDRUGS?
Aarti Drugs Limited has a Quality Score of 97/100, measuring profitability, growth and balance-sheet strength from non-valuation factors.

How we calculate Fair Value

Each company is valued through a stack of independent intrinsic-value models (DCF variants, residual-income, multiples and more), blended into one family-balanced consensus and weighted by how much trustworthy data backs it. A separate quality layer scores the fundamentals. Every input is real reported data — nothing guessed.

Educational research only · not financial advice · no buy/sell recommendation. Model-based estimates are not certainties; their reliability depends on data quality and assumptions.